53 results about "Cough suppressants" patented technology

A mixed-release tablet or capsule formulation including vehicles for the delivery of a plurality of drugs in various combinations of immediate release, extended release, and / or delayed release modes over a predetermined time period have been developed, which provide for controlled release not just of the drugs, but controlled release that is designed to create more effective coordination between the drugs being delivered. The drugs can be any medically and / or physiologically appropriate combination of drugs and active ingredients, preferably decongestant drugs, antihistamines, expectorants, antitussives, cough suppressants, and drying agents.

A system and method for suppressing coughs, congestion and related symptoms is provided. The composition sprayed into the oral cavity may contain a cough suppressant and other ingredients such as decongestants, flavorings, sweeteners, stablizers, and / or preservatives. The composition is sprayed into the oral cavity utilizing a spray pattern having a spray pattern ratio from about 1.0 to about 1.19. The method of application comprises multiple applications of the composition every four to six hours according to condition severity and a user's age characteristics.

A cough suppressant garment may be worn around the neck of the user. The cough suppressant garment may have three layers, and one or more of the three layers may be manufactured from a woven material, such as, for example, cotton. An end of the cough suppressant garment may reversibly attach to an opposite end of the cough suppressant garment to maintain a position of the cough suppressant garment on the neck of the user.

Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole. Furthermore, the metabolic derivatives of astemizole, in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, or in combination with a decongestant, cough suppressant / antitussive or expectorant, are useful for the treatment of cough, cold, cold-like, and / or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith, without the concomitant liability of adverse effects associated with astemizole.

The invention provides a resolution method of racemic 1-(4-methoxybenzyl)-octahydro-isoquinoline by (R)-2-(6-methoxy-2- naphthyl) propionic acid with good yield, wherein the racemic 1-(4-methoxybenzyl)-octahydro-isoquinoline is a key intermediate for synthetizing a cough-relieving medicine dextromethorphan. A resolving agent and unneeded isomers of octahydro-isoquinoline can well be recovered.

Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole. Furthermore, the metabolic derivatives of astemizole, in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, or in combination with a decongestant, cough suppressant / antitussive or expectorant, are useful for the treatment of cough, cold, cold-like, and / or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith, without the concomitant liability of adverse effects associated with astemizole.

An antibacterial breathing strip for nasal decongestant and cough suppressant includes a flexible sheet and an enclosing panel that is traversed with a plurality of ventilation openings. The flexible sheet and the enclosing panel are perimetrically connected to each other while enveloping a filter pad that is saturated with a quantity of antibiotic ointment. The antibacterial breathing strip is intended to externally couple with a mask so that when an individual breathes into the mask the user aromatically inhales the ointment properties, which is controlled and released from the breathing strip via designated ventilation openings, to promote nasal decongestant, suppressing coughs, the removing of sinus pressure, and the removing of sinus headaches and bronchitis.

A cough catching apparatus includes a body for securing to a hand of an individual, the body having an outer surface, an area on the outer surface having a material thereon, and a disinfectant infused into the material. The body may be a glove body. The glove body may have an opening for inserting a hand into the glove body and a plurality of finger openings. The area may be a palm area, a top of hand area, or may include both a palm area and a top of hand area.

The present invention provides one kind of health wine with health functions of reducing phlegm, relieving cough and relieving asthma. It is prepared with ten kinds of Chinese medicinal materials, including Indian azalea, Chinese yam, lily, fritillary, licorice, etc in certain weight proportion. The present invention has integral functions of reducing phlegm, relieving cough and relieving asthma, fast acting, no toxic side effect and other advantages.

The invention discloses a medicinal composition. The medicinal composition mainly comprises momordica grosvenori, pinecone, hydrangea aspera don, mango leaves and ephedra. The medicinal composition has an obvious effect of expelling phlegm and inhibiting cough, and can be prepared into various oral preparations which are beneficial to administration of patients.

The invention discloses a series of substituted phloroglucinol derivatives with a structure shown as the general formula (I) in the specification, and a pharmaceutically acceptable salt thereof, wherein in the general formula (I), A is selected from H, methyl, ethyl or propyl; B1 is selected from H, allyl or natural glycosides disaccharides; B2 and B3 are respectively selected from H or allyl; and X-Y represents that two carbon atoms are connected by a single bond or a double bond. The invention further provides a preparation method of the compounds, and applications of the compounds to preparation of drugs for improving the function of respiratory systems, in particular cough-relieving drugs. Experiments prove that the derivatives, disclosed by the invention, have remarkable cough-relieving effect, no clinical addiction, stable physicochemical property and good prospect as clinical cough-relieving medicine, and are simple in synthetic process and suitable for large-scale production.

A double-headed, closed-mouth cough suppressant and cold relief device in which an individual having the symptoms of a cough is able to suppress the cough by inserting the device into an open mouth, and by sucking on one end of the device, is able to release a menthol medicament disposed within the device to thereby suppress a cough. Additionally, by sucking on another end of the device a eucalyptus medicament is released to thereby relieve a sore throat. By suppressing the cough, the device prevents the spread of germs to the immediate environment.

The invention discloses a pharmaceutical composition and a preparation method, a preparation and application thereof.The pharmaceutical composition comprises, by weight, 8-12 parts of Folium Mori, 5-7 parts of Almond, 10-14 parts of Radix Adenophorae, 8-12 parts of Radix Ophiopogonis, 8-12 parts of Bulbus Fritillariae Thunbergii, 10-20 parts of Rhizoma Phragmitis, 10-20 parts of Semen Coicis, 10-20 parts of wax gourd seed, 2-4 parts of Pericarpium Citri Reticulatae, 8-12 parts of Poria, 8-12 parts of processed pinellia tuber, 10-20 parts of stir-fried Fructus Setariae Germinatus,10-20 parts of roasted Fructus Hordei Germinatus and is prepared through pretreatment, uniform mixing, drying and grinding prior to sieving.The preparation method includes the steps of pretreatment, drying and grinding prior to sieving.The preparation can be powder, tablets, capsules, granules, oral liquid, dripping pills or honeyed pills prepared by adding pharmaceutically acceptable minor ingredients into the pharmaceutical composition.The application refers to application of the pharmaceutical composition to preparation of heat-clearing, dryness-moistening and cough-relieving medicines.The pharmaceutical composition is capable of clearing heat, nourishing yin, moistening dryness and relieving cough through compatibility of all traditional Chinese medicines in the formula.

A cough suppressor according to the present invention includes a chewable inner layer having a predetermined flavor. Preferably, the inner layer is chewing gum. The cough suppressor also includes an active layer situated outside the inner layer and that includes a cough suppressant. In addition, a buffer layer completely separates the inner layer from the active layer. The buffer layer includes a predetermined flavor and ensures that the active layer does not interfere with the flavor of the inner layer. According to another embodiment, a cough suppressant system includes the cough suppressor and one or more auxiliary flavor tablets, each of which includes a desirable flavor such that this flavor may be selectively maintained long after the flavor of the inner layer is consumed. A cough suppressant liquid may be included for application to the flavor tablets.

The present invention relates to a compound of formula (I) (wherein all symbols have the same meanings as described hereinbefore). The compound antagonizes cysLT 2 and therefore, it is useful as an agent for the prevention and / or treatment of respiratory diseases such as bronchial asthma, bronchial asthma, chronic obstructive pulmonary disease, pneumonectasia, chronic bronchitis, pneumonia (e.g. interstitial pneumonitis etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), and the like, or as an expectorant or antitussives.

A device for adding a flavor and / or cough suppressant component to an inhaler is described. The device includes a housing having an interior chamber, wherein the housing includes at least one air inlet and at least one air outlet connected to the interior chamber, thereby forming an airflow pathway through the interior chamber, and at least one flavoring and / or cough suppressant component positioned within the interior chamber, wherein the housing is attachable to an exterior surface of an inhaler having at least one air inlet, such that the at least one air outlet of the device aligns with the at least one air inlet of the inhaler to form an airflow path through the device and into the inhaler.

The invention discloses an online sweeping-micellar electrokinetic chromatography method for separating and measuring protocatechuic acid in acute bronchitis syrup. In micelle capillary electrophoresis, the electrophoresis conditions are that the buffer system refers to 20mmol / L sodium dihydrogen phosphate, 80mmol / L SDS and 12.5 percent (V / V) of acetonitrile with the pH value of 2.2; the detection wavelength is 225nm; the ambient temperature is 25 DEG C. The online sweeping-micellar electrokinetic chromatography method comprises the following steps: diluting a to-be-detected standard substance and sample solution to a proper concentration by using water, wherein the separation voltage is -20kV; and performing gravity injection, wherein the injection height is 16cm, and the injection time is 60 seconds; and the detection limit of protocatechuic acid is 15.96mu g / L. The method disclosed by the invention has the beneficial effects that the online sweeping-micellar electrokinetic chromatography method has good enrichment effect and detection limit, and the method is simple, rapid, high in sensitivity and high in reproducibility and can be used for separating protocatechuic acid and measuring content of protocatechuic acid in cough medicines.

The invention belongs to the technical field of health-care food, and particularly relates to oral thick paste with effects of clearing lung and relieving cough and a preparation method thereof, and the oral thick paste comprises the following components: 30-50 parts of radix peucedani, 30-50 parts of fructus perillae, 30-50 parts of caulis bambusae in taeniam, 30-50 parts of semen lepidii, 10-30 parts of semen armeniacae amarae, 30-50 parts of platycodon grandiflorum, 30-50 parts of exocarpium citri rubrum, 100-200 parts of folium eriobotryae, 50-100 parts of loquat honey, 300-500 parts of Dangshan pears, 100-200 parts of kumquats, 100-200 parts of passion fruits, and 1780 to 5300 parts of pure water. The oral thick paste is prepared by combining various pure natural traditional Chinese medicinal materials and fruits, decocting and concentrating, does not contain antibiotics and western medicine cough-relieving medicines, does not have toxic or side effects and does not generate dependence, all the components are matched with one another and have respective functions, the effects of diminishing inflammation, relieving asthma, clearing away the lung-heat, moistening dryness, relieving cough and reducing sputum are achieved together, the purpose of treating chronic cough is achieved, and the oral thick paste is convenient to take, can be eaten for a long time, and is safe and efficient.

The invention provides an anti-inflammation and cough-suppressant traditional Chinese medicine. The anti-inflammation and cough-suppressant traditional Chinese medicine is prepared from, by weight, 5-10 parts of bulbus fritillariae cirrhosae, 5-10 parts of licorice root, 5-10 parts of perilla leaves, 2-6 parts of rhizoma acori graminei, 3-5 parts of periostracum cicada, 2-8 parts of stir-frying semen armeniacae amarae, 1-2 parts of ramulus acaciae, 1-2 parts of fructus aristolochiae, 4-8 parts of rhizoma pinelliae, 5-10 parts of radix rubiae, 2-5 parts of herba houttuyniae, 3-5 parts of spinagleditsiae, 5-10 parts of dried ginger, 5-10 parts of rhizoma acori graminei, 5-10 parts of herba schizonepetae, 2-5 parts of bamboo juice, 3-5 parts of flos farfarae and 5-15 parts of saccharose. Themedicine efficacies of the medicine materials are complementary, the anti-inflammation and cough-suppressant traditional Chinese medicine has the functions of diminishing inflammation, facilitating the lung, clearing away heat, reducing phlegm and relieving cough and asthma, the immunity is improved, and the anti-inflammation and cough-suppressant traditional Chinese medicine is safe and free oftoxic and side effects.

The invention discloses an online sweeping-micellar electrokinetic chromatography method for separating and measuring ferulic acid in acute bronchitis syrup. In micelle capillary electrophoresis, the electrophoresis conditions are that the buffer system refers to 20mmol / L sodium dihydrogen phosphate, 80mmol / L SDS, and 12.5 percent of acetonitrile with the pH value of 2.2; the detection wavelength is 225nm; the ambient temperature is 25 DEG C. The online sweeping-micellar electrokinetic chromatography method comprises the following steps: diluting a to-be-detected standard substance and sample solution into a proper concentration by using water, wherein the separation voltage is -20kV; and performing gravity injection, wherein the injection height is 16cm, and the injection time is 60 seconds; and the detection limit of ferulic acid is 109.95mu g / L. The method disclosed by the invention has the beneficial effects that the online sweeping-micellar electrokinetic chromatography method has good enrichment effect and detection limit, and the method is simple, rapid, high in sensitivity and high in reproducibility and can be used for separating ferulic acid and measuring content of ferulic acid in cough medicines.

The invention discloses a lozenge. The lozenge is prepared from, by weight, 100-150 parts of grape syrup, 20-30 parts of tendril-leaved fritillary bulb, 15-20 parts of loquat, 10-15 parts of ganodermalucidum powder, 5-10 parts of dendrobium candicum, 3-5 parts of rhizoma coptidis, 3-5 parts of rhizoma anemarrhenae, 20-50 parts of honey and 30-50 parts of white sugar. The lozenge adopts a mode ofparticle sugar, can be carried and daily taken conveniently, does not need brewing or boiling, and is very convenient; the tendril-leaved fritillary bulb, the loquat and the rhizoma coptidis all havea good cough suppressant effect, and the ganoderma lucidum powder, the dendrobium candicum, the rhizoma anemarrhenae and other nourishing medicinal materials assist so that not only the cough is suppressed, but also the physical quality of a patient is improved, the patient can better absorb a medicine capable of relieving the cough, thereby obviously improving the effect of relieving cough, the therapeutic effect is quick, and the treatment cycle is short.

The invention relates to a pharmaceutical composition for preventing phlegm from forming and stopping coughing. In particular to application of glycyl prolyl serine to preparation of a medicine for preventing phlegm from forming and stopping cough, a medicine composition containing glycyl prolyl serine and used for preventing phlegm from forming and stopping cough and a preparation method of the medicine composition. The phlegm reducing and cough stopping effects of glycyl prolyl serine are found for the first time, the glycyl prolyl serine is further prepared into the oral preparation, and it is proved through a mouse toxicity test, a mouse cough model, a guinea pig cough model, a mouse expectoration test model and a beagle cough phlegm test model that after the glycyl prolyl serine is prepared into the oral pharmaceutical composition, the effect of reducing phlegm and stopping cough is achieved. The obvious effects of reducing phlegm and stopping coughing are achieved.

The antitussive and bronchodilator use for an enaminone ester relates to the use of ethyl 4-[(4-chlorophenyl)amino]-6-methyl-2-oxocyclohex-3-en-1-oate (also referred to as “enaminone E121”) for treatment of respiratory conditions, and particularly to use of the ester as the active ingredient in a cough suppressant for nonproductive cough. The ester may be used to achieve an antitussive effect, a bronchodilator effect, or both in a patient in need thereof. The ester may be formulated in any desired delivery form (such as a tablet, a capsule, a time-release capsule, a syrup, a liquid, an injection, a spray, or an inhalant), and be combined with any suitable pharmaceutical carrier, vehicles, binders, fillers, disintegrators, lubricants, solubilizers, emulsifiers, surfactants, and other excipients.